About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

HOPE Against Cancer Recurrence in HCC | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGPhase 4NCT06717919

HOPE Against Cancer Recurrence in HCC

Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrenc...

Lead sponsor: Philipp Dutkowski•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Philipp Dutkowski, Professor

CONTACT

0041 61 777 73 06 philipp.dutkowski@clarunis.ch

Sponsors

Lead Sponsor

Philipp Dutkowski

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult recipients (\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnetic resonance imaging or computer tomography of the liver or biopsy proven),
•within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point of liver transplantation,
•written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC

Exclusion Criteria

•Donation after circulatory death (DCD) liver grafts
•Combined liver transplants
•Partial liver transplants
•Combined or mixed hepatocellular cholangiocarcinoma (cHCC-CCC) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant
•Systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors
•Post-transplant treatment with mTOR inhibitors
•Acute and unexpected medical contraindications
•Pregnancy
•Cold storage time of \> 10 hours (both study arms)

Related studies

RECRUITINGPhase 2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

NCT07422753 · Hepatocellular Carcinoma (HCC)

RECRUITINGPhase 1/2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264 · Cancer, Colorectal Cancer, and more

RECRUITINGPhase 1

An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma

NCT07493044 · Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma

RECRUITINGPhase 1

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650 · Hepatocellular Carcinoma (HCC)

Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis

NCT07469319 · Hepatocellular Carcinoma (HCC), Cirrhosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 16, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE4

Enrollment220

Start dateAug 2025

Last updatedDec 16, 2025

Condition

Liver Transplantation HCC Oncological Outcomes

Locations shown

Rutgers New Jersey Medical School (New York)

New York, New York

Cleveland Clinic

Cleveland, Ohio

Medical University of Innsbruck

Innsbruck

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions